Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia

Giuseppe Ristagno, Cristina Santonocito, Yongqin Li, Giovanni Li Volti, Antonino Gullo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Outcomes of victims of cardiac arrest or acute myocardial ischemic events have improved with advances in medical therapy. Heart failure, however, remains a leading cause of morbidity and mortality after these conditions have occurred. Clinical features may be useful for predicting patients who are at risk of developing such complications, but they lack of sensitivity and specificity. Biomarkers have been therefore suggested as means to provide relevant prognostic information. The more commonly used biomarkers after cardiovascular ischemic events, including cardiac arrest, are creatin kinases and troponins. In addition, natriuretic peptides and C-reactive protein have gained great interest and now sufficient data has been collected such to justify their clinical applicability. Finally, several other novel biomarkers, to be used after resuscitation from cardiac arrest or more generally after a myocardial ischemic event, have been anticipated. Nevertheless, the "perfect" biomarker, able to provide diagnosis and prognosis with high sensitivity and specificity does not exit. A multimarker strategy that categorizes patients based on the number of elevated biomarkers at presentation is therefore suggested.

Original languageEnglish
Pages (from-to)373-391
Number of pages19
JournalFrontiers in Bioscience - Scholar
Volume2 S
Issue number1
Publication statusPublished - Jan 1 2010

Fingerprint

Biomarkers
Heart Arrest
Myocardial Ischemia
Wounds and Injuries
Resuscitation
Sensitivity and Specificity
Natriuretic Peptides
Troponin
C-Reactive Protein
Phosphotransferases
Heart Failure
Morbidity
Mortality

Keywords

  • Biomarkers
  • Cardiac arrest
  • Cardiopulmonary resuscitation
  • Heart
  • Myocardial ischemia
  • Reperfusion

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Ristagno, G., Santonocito, C., Li, Y., Volti, G. L., & Gullo, A. (2010). Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia. Frontiers in Bioscience - Scholar, 2 S(1), 373-391.

Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia. / Ristagno, Giuseppe; Santonocito, Cristina; Li, Yongqin; Volti, Giovanni Li; Gullo, Antonino.

In: Frontiers in Bioscience - Scholar, Vol. 2 S, No. 1, 01.01.2010, p. 373-391.

Research output: Contribution to journalArticle

Ristagno, G, Santonocito, C, Li, Y, Volti, GL & Gullo, A 2010, 'Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia', Frontiers in Bioscience - Scholar, vol. 2 S, no. 1, pp. 373-391.
Ristagno, Giuseppe ; Santonocito, Cristina ; Li, Yongqin ; Volti, Giovanni Li ; Gullo, Antonino. / Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia. In: Frontiers in Bioscience - Scholar. 2010 ; Vol. 2 S, No. 1. pp. 373-391.
@article{923eff2c8fba47a2816b8d09d03f437d,
title = "Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia",
abstract = "Outcomes of victims of cardiac arrest or acute myocardial ischemic events have improved with advances in medical therapy. Heart failure, however, remains a leading cause of morbidity and mortality after these conditions have occurred. Clinical features may be useful for predicting patients who are at risk of developing such complications, but they lack of sensitivity and specificity. Biomarkers have been therefore suggested as means to provide relevant prognostic information. The more commonly used biomarkers after cardiovascular ischemic events, including cardiac arrest, are creatin kinases and troponins. In addition, natriuretic peptides and C-reactive protein have gained great interest and now sufficient data has been collected such to justify their clinical applicability. Finally, several other novel biomarkers, to be used after resuscitation from cardiac arrest or more generally after a myocardial ischemic event, have been anticipated. Nevertheless, the {"}perfect{"} biomarker, able to provide diagnosis and prognosis with high sensitivity and specificity does not exit. A multimarker strategy that categorizes patients based on the number of elevated biomarkers at presentation is therefore suggested.",
keywords = "Biomarkers, Cardiac arrest, Cardiopulmonary resuscitation, Heart, Myocardial ischemia, Reperfusion",
author = "Giuseppe Ristagno and Cristina Santonocito and Yongqin Li and Volti, {Giovanni Li} and Antonino Gullo",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "2 S",
pages = "373--391",
journal = "Frontiers in Bioscience - Scholar",
issn = "1945-0516",
publisher = "Frontiers in Bioscience",
number = "1",

}

TY - JOUR

T1 - Biomarkers of myocardial injury after cardiac arrest or myocardial ischemia

AU - Ristagno, Giuseppe

AU - Santonocito, Cristina

AU - Li, Yongqin

AU - Volti, Giovanni Li

AU - Gullo, Antonino

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Outcomes of victims of cardiac arrest or acute myocardial ischemic events have improved with advances in medical therapy. Heart failure, however, remains a leading cause of morbidity and mortality after these conditions have occurred. Clinical features may be useful for predicting patients who are at risk of developing such complications, but they lack of sensitivity and specificity. Biomarkers have been therefore suggested as means to provide relevant prognostic information. The more commonly used biomarkers after cardiovascular ischemic events, including cardiac arrest, are creatin kinases and troponins. In addition, natriuretic peptides and C-reactive protein have gained great interest and now sufficient data has been collected such to justify their clinical applicability. Finally, several other novel biomarkers, to be used after resuscitation from cardiac arrest or more generally after a myocardial ischemic event, have been anticipated. Nevertheless, the "perfect" biomarker, able to provide diagnosis and prognosis with high sensitivity and specificity does not exit. A multimarker strategy that categorizes patients based on the number of elevated biomarkers at presentation is therefore suggested.

AB - Outcomes of victims of cardiac arrest or acute myocardial ischemic events have improved with advances in medical therapy. Heart failure, however, remains a leading cause of morbidity and mortality after these conditions have occurred. Clinical features may be useful for predicting patients who are at risk of developing such complications, but they lack of sensitivity and specificity. Biomarkers have been therefore suggested as means to provide relevant prognostic information. The more commonly used biomarkers after cardiovascular ischemic events, including cardiac arrest, are creatin kinases and troponins. In addition, natriuretic peptides and C-reactive protein have gained great interest and now sufficient data has been collected such to justify their clinical applicability. Finally, several other novel biomarkers, to be used after resuscitation from cardiac arrest or more generally after a myocardial ischemic event, have been anticipated. Nevertheless, the "perfect" biomarker, able to provide diagnosis and prognosis with high sensitivity and specificity does not exit. A multimarker strategy that categorizes patients based on the number of elevated biomarkers at presentation is therefore suggested.

KW - Biomarkers

KW - Cardiac arrest

KW - Cardiopulmonary resuscitation

KW - Heart

KW - Myocardial ischemia

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=77957291660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957291660&partnerID=8YFLogxK

M3 - Article

C2 - 20036954

AN - SCOPUS:77957291660

VL - 2 S

SP - 373

EP - 391

JO - Frontiers in Bioscience - Scholar

JF - Frontiers in Bioscience - Scholar

SN - 1945-0516

IS - 1

ER -